Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#HRRGeneMutations

Home » #HRRGeneMutations
ASCO-GU Interview | Dr. Xuefeng Qiu: Timely Testing and Treatment, Let mCRPC patients benefit more from PARPi precision treatment

ASCO-GU Interview | Dr. Xuefeng Qiu: Timely Testing and Treatment, Let mCRPC patients benefit more from PARPi precision treatment

Posted by By Mourabit Halima 2024.03.06
Editor's Note: The annual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2024) was held in San Francisco, USA, from January 25 to 27, 2024. The conference presented updates…
Read More
ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

Posted by By Mourabit Halima 2024.03.04
Editor's Note: Following the breakthrough of the PROfound study, which marked the beginning of precision treatment for prostate cancer, the PROpel study has further extended the application of PARP inhibitors…
Read More
Recent Posts
  • Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
  • ESMO China Voice | Professor Jiesong Wang: The iPET-NCCN-IPI Model May Optimize Risk Stratification in Diffuse Large B-Cell Lymphoma
  • ESMO China Voice | Dr. Sicong Zhang: Refractory DLBCL Patients Share Similar Immune Signatures
  • ESMO China Voice | Dr. Cong Sun: Grade 3B Follicular Lymphoma Is an Independent Risk Factor Affecting Both PFS and OS
  • ESMO China Voice | Prof. Liang Wang: CD19/CD22 Bispecific CAR-T Therapy Demonstrates Remarkable Efficacy and Safety in R/R LBCL
Recent Comments
    Archives
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司（香港）
    Scroll to Top